Objective
Tumour immune-therapy has made dramatic improvements in recent years, saving the lives of cancer patients who just a
few years ago would have been considered untreatable. It thereby became apparent that one specific type of immune cell,
so called regulatory T-cells, critically hampers the efficacy of tumour immune-therapy. Tumours, however, attract and exploit
the immune-regulatory function of Tregs to dampen local immune responses and to induce local tolerance.
In recent years, inhibitors that directly target immune-suppressive mechanisms of T cells have found clinical application with
great success. The clinical application of these so called “check-point inhibitors”, however, is accompanied by severe side
effects in treated patients. Thus improvement of the efficacy of current immune-therapeutic treatments is a major unmet
need. This proposal will employ the newest developments in antibody design to target the next generation of biologics right
towards tumour-residential Tregs or directly into the tumour micro-environment itself. In this way we will be able to
specifically shift the local immune suppressive environment within tumours, while leaving tissue homeostasis in noncancerous
tissues unaffected, and thus diminish treatment associated side-effects.
The here proposed project combines the expertise of fundamental immunologist, tumour immunologists and cell biologists
with that of a life-science biotechnology company and that of experts in clinical cancer research to address this aspect. This
group will lead a training network that aims at educating a new generation of researchers, who will be able to bridge the
innovation gap between, on the one hand, early discoveries in tumour-immunology as well as in antibody technology and, on
the other hand, the efficient translation and clinical validations of these findings in patients.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences basic medicine immunology
- medical and health sciences clinical medicine oncology
- medical and health sciences basic medicine physiology homeostasis
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.1.3.1. - Fostering new skills by means of excellent initial training of researchers
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
MSCA-ITN - Marie Skłodowska-Curie Innovative Training Networks (ITN)
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-MSCA-ITN-2017
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
31080 PAMPLONA
Spain
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.